Medico Remedies Share Price ₹34.9 | P/E 22.3

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Medico Remedies

Quarter-by-quarter operating performance

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	27.99	31.47	42.36	29.77	41.32	30.80	39.35	39.49	41.30	38.25	52.64	58.68	56.81
Expenses +	24.82	29.01	39.29	27.04	36.67	27.98	36.94	36.38	34.64	35.43	49.91	54.35	49.66
Operating Profit	3.17	2.46	3.07	2.73	4.65	2.82	2.41	3.11	6.66	2.82	2.73	4.33	7.15
OPM %	11.33%	7.82%	7.25%	9.17%	11.25%	9.16%	6.12%	7.88%	16.13%	7.37%	5.19%	7.38%	12.59%
Other Income +	0.04	0.31	0.96	0.27	0.58	0.29	0.68	1.43	0.29	0.66	1.72	0.68	2.87
Interest	0.21	0.17	0.18	0.22	0.25	0.18	0.21	0.28	0.49	0.28	0.24	0.39	0.90
Depreciation	0.73	0.71	0.71	0.72	0.74	0.75	0.75	0.76	0.77	0.77	0.73	0.79	0.80
Profit before tax	2.27	1.89	3.14	2.06	4.24	2.18	2.13	3.50	5.69	2.43	3.48	3.83	8.32
Tax %	22.47%	29.63%	22.61%	30.10%	26.89%	27.06%	27.23%	25.14%	23.90%	25.51%	25.86%	25.07%	29.69%
Net Profit +	1.77	1.32	2.43	1.45	3.10	1.58	1.55	2.62	4.34	1.82	2.57	2.87	5.86
EPS in Rs	0.21	0.16	0.29	0.17	0.37	0.19	0.19	0.32	0.52	0.22	0.31	0.35	0.71

Financials of Medico Remedies

Annual income statement trend

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales +	51	67	54	61	98	89	122	121	140	145	151	206
Expenses +	48	63	50	58	95	86	117	114	131	132	136	189
Operating Profit	3	4	4	3	3	3	5	7	10	13	15	17
OPM %	6%	5%	7%	6%	3%	3%	4%	6%	7%	9%	10%	8%
Other Income +	0	0	0	1	2	2	1	2	4	2	3	6
Interest	1	1	1	2	1	1	1	1	1	1	1	2
Depreciation	1	1	1	1	2	2	2	2	3	3	3	3
Profit before tax	1	2	2	2	2	2	4	6	10	11	14	18
Tax %	28%	40%	4%	35%	28%	26%	30%	26%	28%	27%	25%	27%
Net Profit +	1	1	2	1	2	2	3	5	7	8	10	13
EPS in Rs	0.25	0.35	0.25	0.15	0.19	0.20	0.31	0.58	0.87	1.00	1.22	1.58
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Financials of Medico Remedies

Capital structure and asset base

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	2	3	4	4	4	4	17	17	17	17	17
Reserves	12	13	13	23	24	26	28	20	27	36	46	59
Borrowings +	8	14	19	13	14	14	15	13	10	8	15	19
Other Liabilities +	14	17	13	20	35	32	28	28	34	36	43	59
Total Liabilities	36	46	48	59	76	75	76	77	87	96	120	153
Fixed Assets +	8	7	7	7	12	13	15	18	22	21	21	20
CWIP	0	0	3	4	1	2	0	0	0	0	0	3
Investments	1	1	0	0	0	0	1	0	1	2	2	2
Other Assets +	27	38	39	48	63	60	59	59	64	73	96	129
Total Assets	36	46	48	59	76	75	76	77	87	96	120	153

Financials of Medico Remedies

Operating, investing and financing cash movement

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	-3	5	5	1	-11	6	8	2	5	6
Cash from Investing Activity +	-3	-5	-4	-3	-17	-2	-7	-3	-3	-5
Cash from Financing Activity +	6	-1	-1	3	18	-6	-2	-0	-1	-1
Net Cash Flow	-0	-0	-0	0	-10	-2	-0	-1	1	1
Free Cash Flow	-4	3	1	-2	-28	3	2	-0	2	1
CFO/OP	-68%	162%	198%	53%	-198%	104%	111%	43%	58%	64%

Financials of Medico Remedies

Working capital efficiency and return ratios

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	53	107	122	102	109	98	82	92	94	125	138	145
Inventory Days	76	63	96	125	74	99	58	76	69	54	90	72
Days Payable	122	106	112	147	149	143	100	113	108	105	117	119
Cash Conversion Cycle	6	64	105	80	33	54	39	54	54	75	111	98
Working Capital Days	21	53	110	88	49	61	50	52	54	74	90	87
ROCE %	10%	11%	10%	9%	8%	8%	10%	15%	21%	21%	21%	23%

Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Medico Remedies Share Price & Earnings Call Analysis